PUSH Fitness & Rehabiliation
Welcome !! PUSH-as-Rx ®™ is leading the field with laser focus supporting our youth sport programs. The PUSH-as-Rx ®™ System is a sport specific athletic program designed by a strength-agility coach and physiology doctor with a combined 40 years of experience working with extreme athletes. At its core, the program is the multidisciplinary study of reactive agility, body mechanics and extreme motion dynamics. Through continuous and detailed assessments of the athletes in motion and while under direct supervised stress loads, a clear quantitative picture of body dynamics emerges. Exposure to the biomechanical vulnerabilities are presented to our team. Immediately, we adjust our methods for our athletes in order to optimize performance. This highly adaptive system with continual dynamic adjustments has helped many of our athletes come back faster, stronger, and ready post injury while safely minimizing recovery times. Results demonstrate clear improved agility, speed, decreased reaction time with greatly improved postural-torque mechanics. PUSH-as-Rx ®™ offers specialized extreme performance enhancements to our athletes no matter the age.

Scientists Inhibit Brain Tumor Cell Growth, Paving Way for New Treatment | Circle of Docs

Glioblastoma is a particularly aggressive form of brain cancer that can be difficult to treat. New research, however, may have found a drug that can inhibit the protein driving its growth.
Researchers may have found a way to inhibit the growth of brain tumors, here shown in an MRI scan.
Glioblastomas are tumors that form out of the “sticky,” supportive tissue of the brain and spinal cord.

Most of the time, glioblastomas are aggressive malignant; they are made of many different types of cells that reproduce very quickly and receive a significant blood supply. The 5-year survival rate is estimated to be less than 10 percent.

Glioblastoma can be difficult to treat because of the heterogenous nature of its cells. Some of the cells may respond to therapy while others may not.

Typically, treatment includes a combination of surgery, radiation, and chemotherapy. So far, this has resulted in a median survival of about 2 to 3 years for patients receiving standard treatment.

Patients with more severe forms of glioblastoma, who receive a combination of drugs and radiation therapy, usually survive for an average of 14.6 months, and the 2-year survival rate is approximately 30 percent. Little can be done to treat recurrent glioblastoma.

In this context, more and more researchers are exploring genetic options for treatment. Recent studies have pointed to mutations in the receptor tyrosine kinase (RTK) genes as the key driver of glioblastoma, but clinical trials aimed specifically at neutralizing these driver mutations were not successful in treating this form of cancer.

However, researchers from the Peter O’Donnell Jr. Brain Institute and Harold C. Simmons Comprehensive Cancer Center may have found a way to inhibit glioblastoma cells.

Their findings were published in the journal Cell Reports.

The team – co-led by Dr. Robert Bachoo, of the Annette G. Strauss Center for Neuro-Oncology at University of Texas Southwestern Medical Center, and Dr. Ralf Kittler, an assistant professor of pharmacology in the Eugene McDermott Center for Human Growth and Development – successfully used a drug to target different proteins that drive the growth of glioblastoma tumors.

Mithramycin inhibits glioblastoma-driving transcription factors

The new study suggests that so far, researchers have mistakenly focused on RTK gene mutations, which are only responsible for starting tumor growth, not for the continued growth of glioblastoma.

“Our work shows that the gene mutations which the pharmaceutical industry and clinicians have been focusing on are essential only for starting tumor growth. Once the tumor has advanced to the stage where patients seek treatment, these mutations are no longer required for continued tumor growth; they are in effect redundant,” explains co-senior author Dr. Bachoo.

Instead of the RTK genes, the new study found three transcription factors to be responsible for glioblastoma: Sox2, Olig2, and Zeb1.

As co-senior author Dr. Kittler explains, the study shows that these “neurodevelopmental transcription factors (master proteins that regulate the activity of hundreds of genes during normal brain development) are reactivated to drive the growth of glioblastoma.”

Dr. Alex Jimenez D.C.,C.C.S.T’s insight:

Glioblastoma can be difficult to treat because of the heterogenous nature of its cells. Some of the cells may respond to therapy while others may not.

Typically, treatment includes a combination of surgery, radiation, and chemotherapy. So far, this has resulted in a median survival of about 2 to 3 years for patients receiving standard treatment.

Now, there is hope. These new studies reveal that limiting transitional factors are a key to preventing cellular growth. This offers a great opportunity of discovery for those suffering with certain forms of brain tumors. 

English EN Spanish ES